Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
about
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaLoss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity.Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cellsStructural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
P2860
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
@en
type
label
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
@en
prefLabel
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
@en
P2093
P2860
P356
P1433
P1476
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2012.351
P577
2012-12-04T00:00:00Z
P5875
P6179
1048401532